Why the study?
The optimal strategy of adjunctive eptifibatide, bolus-only versus bolus-plus-infusion, remains uncertain in ACS patients undergoing PCI on dual antiplatelet therapy, particularly regarding ischemic protection versus bleeding risk.
Does bolus-only eptifibatide provide comparable ischemic protection and reduce bleeding compared to standard bolus-plus-infusion in ACS patients undergoing PCI on dual antiplatelet therapy?
Does bolus-only eptifibatide provide comparable ischemic protection and reduce bleeding compared to standard bolus-plus-infusion in ACS patients undergoing PCI on dual antiplatelet therapy?
In ACS patients undergoing PCI on dual antiplatelet therapy, a bolus-only eptifibatide strategy provides comparable ischemic protection to standard bolus-plus-infusion while significantly reducing minor bleeding.
Answers are grounded in this paper and cite their sources.
Supports bolus-only eptifibatide to reduce minor bleeding in ACS PCI; confirms comparable ischemic protection versus infusion.
Background: Guidelines do not recommend routine glycoprotein IIb/IIIa inhibitors (GPIs), reserving them for high thrombotic-risk or bailout cases. Most acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) are already on dual antiplatelet therapy (aspirin plus clopidogrel). GPIs thus act as adjunctive therapy, providing short-term platelet inhibition. The optimal strategy, bolus-only versus bolus-plus-infusion, remains uncertain, especially in patients at higher bleeding risk. Objective: To evaluate whether bolus-only eptifibatide provides ischemic protection comparable to standard bolus-plus-infusion while reducing bleeding in ACS patients undergoing PCI. Methods: = 81) and were followed for 90 days. The primary outcome, major adverse cardiac events (MACE), included cardiac death, recurrent myocardial infarction, stent thrombosis, or repeat target-vessel revascularization. Secondary endpoints included left ventricular function, mechanical/electrical complications, and bleeding. Major bleeding was defined by TIMI criteria; minor bleeding included clinically apparent non-life-threatening events. Electrical complications were infrequent and comparable. Conclusions: In ACS patients on dual antiplatelet therapy, bolus-only eptifibatide provides ischemic protection comparable to bolus-plus-infusion while reducing minor bleeding, supporting a simplified adjunctive strategy in high thrombotic-risk patients undergoing PCI.
No takes yet. Share an insight, caveat, or question.
Baharvand et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: